摘要
目的探究Her-2阳性乳腺癌临床治疗中曲妥珠单抗联合多西紫杉醇的应用效果。方法将我院2017年10月—2018年9月收治的Her-2阳性乳腺癌患者中选取62例按照入院顺序分两个组,各31例,对照组使用多西紫杉醇治疗,研究组在其基础上增加曲妥珠单抗治疗,对比治疗客观有效率、疾病控制有效率、毒副反应发生率。结果研究组患者临床治疗客观有效率以及疾病控制率均高于对照组,毒副反应发生率低于对照组,各项差异有统计学意义(P <0.05)。结论 Her-2阳性乳腺癌在多西紫杉醇治疗基础上增加曲妥珠单抗能够有效提升临床治疗效果。
Objective To investigate the effect of trastuzumab combined with docetaxel in the clinical treatment of Her-2 positive breast cancer.Methods 62 patients with Her-2 positive breast cancer admitted to our hospital from October 2017 to September 2018 were divided into two groups according to the order of admission,each with 31 cases.The control group was treated with docetaxel,and the research group was on the basis of it to increase trastuzumab.The objective effective rate of treatment,the effective rate of disease control and the incidence of toxic and side effects were compared.Results The objective efficiency and disease control rate of clinical treatment were higher than that of the control group,and the incidence of toxic and side effects was lower than that of the control group,the difference was statistically significant(P<0.05).Conclusion Her-2 positive breast cancer can improve the clinical effect by increasing trastuzumab on the basis of docetaxel.
作者
朱耀宇
ZHU Yaoyu(Western Medicine Storageroom,Heze Municipal Hospital,Heze Shandong 274000,China)
出处
《中国卫生标准管理》
2019年第3期47-48,共2页
China Health Standard Management
